Global IVIg Powder Market Size By Type (2.5g, 1.25g), By Application (Immunodeficiency, Autoimmune Disease), By Region, And Segment Forecasts, 2023 to 2032

The Global IVIg (Intravenous Immunoglobulin) Powder Market was valued at USD 7.1 billion in 2023 and is projected to reach USD 12.4 billion by 2031, expanding at a CAGR of 7.1% during the forecast period (2023–2031). The market is experiencing strong growth driven by the increasing prevalence of immunodeficiency disorders, rising use of immunoglobulin therapies for autoimmune diseases, and advances in plasma fractionation techniques. IVIg powder plays a critical role in treating various conditions such as primary immunodeficiencies, Guillain-Barré syndrome, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy (CIDP), fueling its demand globally.

Drivers:

Rising Incidence of Immunodeficiency and Autoimmune Disorders

The growing number of patients diagnosed with primary and secondary immunodeficiency disorders and autoimmune diseases like lupus and multiple sclerosis is propelling the need for IVIg therapies. IVIg powder is especially effective due to its broad-spectrum immunomodulatory and anti-inflammatory properties.

Growing Geriatric Population

With the aging global population, the prevalence of chronic illnesses and weakened immune systems is increasing, which drives demand for immunoglobulin-based therapies such as IVIg powder.

Advancements in Plasma Collection and Processing

Innovations in plasma fractionation and purification technologies are increasing the availability, safety, and efficacy of IVIg powder, contributing to market expansion.

Restraints:

High Cost of IVIg Therapies

The production of IVIg powder is resource-intensive and costly, often making the therapies expensive and limiting accessibility in low-income regions.

Limited Plasma Supply

IVIg powder is derived from human plasma, and the availability of high-quality plasma donors is limited. This supply constraint impacts production volumes and market scalability.

Opportunity:

Expansion into Emerging Economies

Emerging markets in Asia-Pacific and Latin America offer lucrative growth opportunities due to increasing healthcare infrastructure, government support for rare disease management, and rising awareness of immunotherapy.

Personalized and Targeted Immunotherapy Research

Ongoing research in personalized medicine and targeted immunoglobulin therapy presents new potential for IVIg powder application in rare and niche disease areas, supporting long-term market expansion.

Market by System Type Insights:

By system type, the Liquid Reconstituted IVIg segment held a substantial share in 2023 due to its ease of administration and stable formulation. However, Lyophilized IVIg Powder is gaining traction owing to its longer shelf life, room temperature storage capability, and suitability for distribution in remote or low-resource settings. These benefits are boosting its adoption in both hospital and homecare settings.

Market by End-use Insights:

In terms of end-use, Hospitals & Clinics remained the largest revenue contributor in 2023, accounting for over 60% of the global market. These facilities are the primary centers for administering IVIg therapies for acute and chronic immunological conditions. The Homecare segment is poised for the fastest growth due to rising patient preference for at-home infusion therapies and improvements in healthcare delivery infrastructure.

Market by Regional Insights:

Geographically, North America led the market in 2023, attributed to advanced healthcare systems, high prevalence of autoimmune and immunodeficiency conditions, and favorable reimbursement policies. Asia-Pacific is expected to exhibit the highest CAGR during the forecast period, driven by rising healthcare expenditures, improved access to plasma therapies, and government initiatives to combat rare diseases in countries such as China, India, and South Korea.

Competitive Scenario:

Leading players in the global IVIg powder market include Grifols S.A., CSL Behring, Octapharma AG, Kedrion Biopharma, Bio Products Laboratory (BPL), Takeda Pharmaceutical Company Limited, ADMA Biologics, LFB S.A., and China Biologic Products Holdings, Inc. These companies are engaged in strategic collaborations, R&D investments, and expansion of manufacturing capabilities to meet the growing global demand.

Scope of Work – Global IVIg Powder Market

Key Market Developments:

2023: CSL Behring expanded its immunoglobulin production facilities in Switzerland to meet increasing demand for IVIg therapies worldwide.

2024: Grifols introduced a new high-purity IVIg powder formulation designed for improved reconstitution time and reduced infusion-related reactions.

2025: Octapharma partnered with a network of hospitals across Asia-Pacific to enhance access to IVIg treatments for rare neurological diseases.

FAQs:

What is the current market size of the Global IVIg Powder Market?

The market size was valued at USD 7.1 billion in 2023.

What is the major growth driver of the Global IVIg Powder Market?

The key driver is the rising prevalence of immunodeficiency and autoimmune disorders globally.

Which is the largest region during the forecast period in the Global IVIg Powder Market?

North America holds the largest market share due to advanced healthcare infrastructure and high treatment adoption.

Which segment accounted for the largest market share in the Global IVIg Powder Market?

The Hospitals & Clinics segment led the market in 2023 with over 60% share.

Who are the key market players in the Global IVIg Powder Market?

Key players include CSL Behring, Grifols S.A., Takeda Pharmaceutical, Octapharma AG, and Kedrion Biopharma.